Refining Early Antitumoral Drug Development

The failure rate of development of new drugs in oncology is high, with up to 95% of drugs tested in Phase I not reaching the market. Causes behind this high failure rate are discussed here, and solutions to increase the success in the development of antitumor drugs are suggested.

Bibliographische Detailangaben

Veröffentlicht in:	Trends in pharmacological sciences (Regular ed.) 2018-11, Vol.39 (11), p.922-925
Hauptverfasser:	Ocaña, Alberto, García-Alonso, Sara, Amir, Eitan, Pandiella, Atanasio
Format:	Artikel
Sprache:	eng
Schlagworte:	drug development oncology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!